# QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT

> **NCT07327788** · PHASE2 · RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 38 (estimated)

## Conditions studied

- Hepatecellular Carcinoma
- RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin
- Bevacizumab
- Type VP3/4 Portal Vein Tumor Thrombosis
- Iparomlimab and Tuvonralimab Injection
- QL1706

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab Injection (QL1706)
- **DRUG:** Bevacizumab
- **PROCEDURE:** Hepatic Arterial Infusion Chemotherapy with Raltitrexed and Oxaliplatin (RALOX-HAIC)

## Key facts

- **NCT ID:** NCT07327788
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-25
- **Primary completion:** 2027-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07327788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07327788, "QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3/4 PVTT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07327788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*